Overview
Sapian is Kantify's universal AI engine that overcomes traditional structure-based drug discovery limitations by leveraging hundreds of millions of datapoints to find IP-clean chemistry for challenging therapeutic targets. The platform has been validated across multiple target categories including ion channels, antigens, and ubiquitin-like proteins, and can screen 13 billion compounds in under a day.
Leadership & org chart
In the news
- Last sprint before BIO-Europe in Cologne. The theme of this year for Kantify: accelerating the discovery of molecules for Ion channels and GPCRs with AI. Get in touch with Segolene Martin if you have an undruggable target, regardless of the target family.
- This picture is so misleading that we even debated if I should post it here. Can you see the AlphaFold protein structure prediction behind me? Well, it is precisely to illustrate...that our AI platform Sapian isn't based on the notion of protein or molecular structures. So, don't be misled by this picture, we don't do structure-based drug discovery and that's one of the things that make our technology so orthogonal. This picture was taken during the Health track of the Flanders Technology & Innovation Festival. I explained the
- Last week, the DREAMS webinar gathered 3 companies working on AI for Rare neuromuscular disorders, around François Lamy, Vice-President of patient organization AFM-Téléthon. Our colleague Dr. Rubal Ravinder, Biochemistry Machine Learning Engineer, presented Kantify's AI platform, Sapian and disclosed a first snapshot of our AI-powered target discovery results. These results were obtained through a pioneering collaboration with I-Stem around a rare neuromuscular disorder: LGMD-R2. Dr. Ravinder also introduced the European research
- Most virtual screening tools rely on static 3D protein structures, missing how proteins flex and shift in real biological environments. When targeting flexible pockets, allosteric sites, or proteins with no crystal structure, structure-based small molecule discovery quickly hits its limit. Our AI platform Sapian was trained on billions of molecular and proteomic data points to predict functional outcomes directly from 𝘴𝘦𝘲𝘶𝘦𝘯𝘤𝘦 𝘢𝘭𝘰𝘯𝘦. Without requiring structural prep or 3D snapshots, it enables target-agnostic,
- It feels pretty energizing to see such a concentration of Belgian health tech innovators on a single program. Look it up, and join us if you can. See by yourself how fruitful is the encounter between health and tech. Many thanks for inviting Kantify, Flanders Technology & Innovation Festival & Vlaamse overheid
- Rare neuromuscular disorders present unique diagnostic and therapeutic challenges. As part of the DREAMS Consortium, Kantify is working to bridge this gap using Artificial Intelligence. The webinar held by DREAMS on October 15th will answer to the question about how AI can help accelerate and improve our understanding and therapeutic quest for rare neuromuscular patients. Our speakers GoHun Seo, Rubal Ravinder, 💭 Christopher Rudolf will share actual results obtained with Artificial Intelligence in rare neuromuscular disorders,
- A unique opportunity to learn directly from those using Artificial Intelligence to help rare neuromuscular disorder patients. We'll focus on diagnosis, target discovery and treatment discovery. Beyond the hype, we will be looking at practical results and progress enabled by AI in rare NMD. https://lnkd.in/p/e8f9M2SD Volv Global SA 3billion Kantify AFM-Téléthon Xavier Nissan François Lamy Rubal Ravinder GoHun Seo Changwon Keum 💭 Christopher Rudolf Le Vin Chin
- Historically, drugging the 'undruggable' has been characterized by several key challenges: a lack of target knowledge, scarce or low-quality structural data, and the limitations of traditional high-throughput screening assays. Under these constraints, prioritizing highly probable candidate targets or drugs for experimental validation is essential. Learn from our own Nicolas Maignan whose involvement in using Sapian for target discovery and small molecule drug discovery, at the service rare neuromuscular disorders patients,
Alumni
Nicolas MaignanLead Machine Learning Engineer
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.